S-1360: Shionogi-GlaxoSmithKline

Current Opinion in Investigational Drugs

Volumn 4, Issue 2, 2003, Pages 206-209

  Billich, Andreas ^a  

^a Novartis Research Institute   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

1 (5 CHLOROINDOL 3 YL) 3 HYDROXY 3 (2H TETRAZOL 5 YL)PROPENONE; 1 [5 (4 FLUOROBENZYL) 2 FURYL] 3 (1,2,4 TRIAZOL 3 YL) 1,3 PROPANEDIONE; 4 [1 (4 FLUOROBENZYL) 2 PYRROLYL] 2,4 DIOXOBUTYRIC ACID; DRUG ANALOG; INTEGRASE; INTEGRASE INHIBITOR; L 708906; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PLACEBO; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; ENZYME INHIBITION; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION;

ANTI-HIV AGENTS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; FURANS; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HUMANS; TRIAZOLES;

EID: 0037303182     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. 192750 A simple and rapid method for preliminary evaluation of in vivo efficacy of anti-HIV compounds in mice Sato A, Kodama M, Abe K, Miki S, Nishimura M, Suyama A, Ogata M, Toyoda T, Sugimoto H, Yoshie O, Fujiwara T Antiviral Res 1995 27 1-2 151-163
2. 361334 Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: A platform for antiviral drug design. Goldgur Y, Craigie R, Cohen GH, Fujiwara T, Yoshinaga T, Fujishita T, Sugimoto H, Endo T, Murai H, Davies DR Proc Natl Acad Sci USA 1999 96 23 13040-13043 The structure of a complex of HIV-1 integrase core domain with 5CITEP at 2.1-̊ resolution is reported. The The inhibition binds centrally at the active site of the integrase and makes a number of close contacts with the protein, with only minor changes in the protein occurring on binding.
3. 362362 Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, Grobler JA, Espeseth A, Gabryelski L, Schlief W, Blau C, Miller MD Science 2000 287 5453 646-650 This report includes a thorough analysis of the mechanism of the 1,3-dicarbonyl compound inhibitors of HIV-1 integrase and viral replication and also includes how HIV-1 integrase was discovered by high-throughput screening.
4. 398750 Drugs under development. Shionogi & Co Ltd Company World Wide Web Site 2001 February 13
5. 410117 Shionogi USA established. Pharma JPN 2001 1746 4
6. 416762 GSK and Shionogi to enter global multi-product development and commercialization alliance: GSK-Shionogi joint venture to be formed. GlaxoSmithKline plc Press Release 2001 July 24
7. 426569 GlaxoSmithKline results announcement for the third quarter 2001. GlaxoSmithKline plc Press Release 2001 October 23
8. 426822 Final agreement reached on GSK-Shionogi joint venture project. Shionogi & Co Ltd Press Release 2001 October 24 Shionogi and GSK reached a final agreement on a joint venture to co-develop several compounds, including S-1360.
9. 426830 Product development pipeline: October 2001. GlaxoSmithKline plc Company Publication 2001 October 23
10. 430179 Shionogi to increase overseas sales to 10% of total sales in 2005. Pharma Jpn 2001 1771 5
11. 443224 Retroviruses and opportunistic infections - Ninth conference, new antiviral agents, Seattle, WA, USA. Este JA IDDB Meeting Report 2002 February 24-28
12. 446957 Research & development: Product pipeline. GlaxoSmithKline plc Company World Wide Web Site 2002 March 28
13. 447882 In vitro activity of a new HIV-1 integrase inhibitor in clinical development. Yoshinaga T, Sato A, Fujishita T, Fujiwara T Ninth Int Conf Retroviruses Opportunistic Infect 2002 February 24-28 Abs 8
14. 452543 Supplement to financial statements, 2001. Taiwan Shionogi & Co Ltd Company Publication 2002 May 20
15. 456687 Patented small molecule inhibitors of HIV-1 integrase: A 10-year saga. Neamati N Exp Opin Ther Pat 2002 12 5 709-724
16. 457541 Results of first human trial of a new class of anti-HIV drugs reported by Shionogi-GlaxoSmithKline Pharmaceuticals LLC. GlaxoSmithKline plc Press Release 2002 July 09
17. 459337 Shionogi-GSK announces 1st clinical trial results for new anti-HIV drug. Pharma Jpn 2002 1804 16
18. 460177 New drugs in the R&D pipeline. Pharma Jpn 2002 1806 1-20
19. 14C]S-1360, a new HIV-1 integrase inhibitor, in healthy subjects. Kobayashi Y, Leese P, Russell T, Frankovic C, Fujiwara T ICAAC 2002 Abs H184
20. 469783 R&D: Pipeline - Drugs under development. Shionogi & Co Ltd Company Publication 2002 November 11
21. 47554 Pan Europe-Pharmaceutical Model Book: Stable interest rates: Stable sector. Culverwell J, Barnes N, Upadhya R, Schmidt A, Woodhouse P, Southwood H Merril Lynch & Co 2002 September 23 Merrill Lynch report estimating pharmaceutical product sales including those from the GlaxoSmithKline pipeline.